1. Nätkin, R, Pennanen, P, Syvälä, H, Bläuer, M, Kesseli, J, Tammela, TLJ et al.. Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation. PLoS One. 2023;18 (2):e0281645. doi: 10.1371/journal.pone.0281645. PubMed PMID:36809527 .
  2. Saralahti, AK, Harjula, SE, Rantapero, T, Uusi-Mäkelä, MIE, Kaasinen, M, Junno, M et al.. Characterization of the innate immune response to Streptococcus pneumoniae infection in zebrafish. PLoS Genet. 2023;19 (1):e1010586. doi: 10.1371/journal.pgen.1010586. PubMed PMID:36622851 PubMed Central PMC9858863.

Search PubMed


  1. Sjöström, M, Zhao, SG, Levy, S, Zhang, M, Ning, Y, Shrestha, R et al.. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. Cancer Res. 2022;82 (21):3888-3902. doi: 10.1158/0008-5472.CAN-22-1123. PubMed PMID:36251389 PubMed Central PMC9627125.
  2. Kukkonen, K, Autio-Kimura, B, Rauhala, H, Kesseli, J, Nykter, M, Latonen, L et al.. Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen. Endocr Relat Cancer. 2022;29 (12):717-733. doi: 10.1530/ERC-22-0108. PubMed PMID:36219867 PubMed Central PMC9644224.
  3. Buhigas, C, Warren, AY, Leung, WK, Whitaker, HC, Luxton, HJ, Hawkins, S et al.. The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates. Mol Cancer. 2022;21 (1):183. doi: 10.1186/s12943-022-01644-3. PubMed PMID:36131292 PubMed Central PMC9494848.
  4. Rautajoki, KJ, Jaatinen, S, Tiihonen, AM, Annala, M, Vuorinen, EM, Kivinen, A et al.. PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas. Sci Rep. 2022;12 (1):14083. doi: 10.1038/s41598-022-14977-2. PubMed PMID:35982066 PubMed Central PMC9388569.
  5. Koivisto, M, Tolvanen, TA, Toimela, T, Miinalainen, I, Kiviaho, A, Kesseli, J et al.. Functional human cell-based vascularised cardiac tissue model for biomedical research and testing. Sci Rep. 2022;12 (1):13459. doi: 10.1038/s41598-022-17498-0. PubMed PMID:35931748 PubMed Central PMC9355975.
  6. Herberts, C, Annala, M, Sipola, J, Ng, SWS, Chen, XE, Nurminen, A et al.. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature. 2022;608 (7921):199-208. doi: 10.1038/s41586-022-04975-9. PubMed PMID:35859180 .
  7. L B Almeida, B, M Bahrudeen, MN, Chauhan, V, Dash, S, Kandavalli, V, Häkkinen, A et al.. The transcription factor network of E. coli steers global responses to shifts in RNAP concentration. Nucleic Acids Res. 2022;50 (12):6801-6819. doi: 10.1093/nar/gkac540. PubMed PMID:35748858 PubMed Central PMC9262627.
  8. Cao, S, Wang, JR, Ji, S, Yang, P, Dai, Y, Guo, S et al.. Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nat Biotechnol. 2022;40 (11):1624-1633. doi: 10.1038/s41587-022-01342-x. PubMed PMID:35697807 PubMed Central PMC9646498.
  9. Fonseca, NM, Van der Eecken, K, Herberts, C, Verbeke, S, Ng, SWS, Lumen, N et al.. Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer. JCO Precis Oncol. 2022;6 :e2100543. doi: 10.1200/PO.21.00543. PubMed PMID:35507889 .
  10. Rodriguez-Martinez, A, Vuorinen, EM, Shcherban, A, Uusi-Mäkelä, J, Rajala, NKM, Nykter, M et al.. Novel ZNF414 activity characterized by integrative analysis of ChIP-exo, ATAC-seq and RNA-seq data. Biochim Biophys Acta Gene Regul Mech. 2022;1865 (3):194811. doi: 10.1016/j.bbagrm.2022.194811. PubMed PMID:35318951 .
  11. Ruusuvuori, P, Valkonen, M, Kartasalo, K, Valkonen, M, Visakorpi, T, Nykter, M et al.. Spatial analysis of histology in 3D: quantification and visualization of organ and tumor level tissue environment. Heliyon. 2022;8 (1):e08762. doi: 10.1016/j.heliyon.2022.e08762. PubMed PMID:35128089 PubMed Central PMC8800033.
  12. Bacon, JVW, Müller, DC, Ritch, E, Annala, M, Dugas, SG, Herberts, C et al.. Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy. Eur Urol Oncol. 2022;5 (6):677-686. doi: 10.1016/j.euo.2021.11.002. PubMed PMID:34895867 .

Search PubMed